A clinical trial for treatment of a range of cancers using patients' own blood cells began Monday at Keio University Hospital in Tokyo, with its commercialization eyed in nine years or so.The treatment uses blood cells linked to the immune system response. The method is studied by researchers around the world as a promising therapy with a long-term efficacy and reduced toxicity.The blood cells are processed to better activate natural killer cells before being infused back into cancer patients. In mouse experiments, activated natural killer cells successfully triggered prolonged responses of…READ FULL ARTICLE
